Johnson & Johnson acquires Intra-Cellular Therapies — neuroscience drug blockbuster signals Big Pharma conviction in CNS
Summary
Johnson & Johnson's January 2026 acquisition of Intra-Cellular Therapies — the New York-based biotech focused on CNS drug development, best known for Caplyta (lumateperone) for schizophrenia and bipolar depression — was identified by Delix Therapeutics' head of strategy as a defining moment showing that 2025 was a pivotal year for neuroscience. The acquisition adds a commercially successful CNS drug franchise to J&J's neuroscience portfolio alongside their DBS (through Cereval/Abbott) exposure. The deal signals that major pharmaceutical companies are betting on CNS as a commercial growth driver.
Why it matters
J&J acquiring a CNS biotech with a marketed product in schizophrenia and bipolar depression signals that the Alzheimer's disease-modifying therapy wave has convinced Big Pharma that CNS is now commercially viable at scale — not just the high-science graveyard it was considered for two decades. The Intra-Cellular acquisition will accelerate J&J's interest in complementary neurostimulation and neuromodulation approaches that can work synergistically with their pharmacological CNS portfolio.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial